KINE 101C
Alternative Names: KINE-101CLatest Information Update: 25 Feb 2025
At a glance
- Originator Kine Sciences
- Class Peptides; Small molecules
- Mechanism of Action Regulatory T-lymphocyte modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic inflammatory demyelinating polyradiculoneuropathy
Most Recent Events
- 21 Feb 2025 Phase-I/II clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy in South Korea (unspecified route) (Kine Sciences pipeline, February 2025)
- 21 Jun 2022 Phase-I clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (unspecified route) (Kine Sciences pipeline, June 2022)
- 21 Jun 2022 Kine Sciences plans a phase I/II trial for Neurological disorders (Kine Sciences pipeline, June 2022)